CAR T therapy has been in development for over 20 years. The first CAR T therapy is now available for the treatment of multiple myeloma. The ide-cel treatment (now called Abecma) is now FDA approved for multiple myeloma relapsed or refractory patients. In this show, Dr. Noopur Raje of Mass General Hospital will share how the CAR T cell therapy works, outcome data from clinical trials, a review of patients who are eligible to join and when patients should consider the therapy in context of other therapies. Ide-cel (Abecma) is a product developed by Bristol Myers Squibb and blubird bio.
Thanks to our episode sponsor, Oncopeptides
HealthTree Podcast for Multiple Myeloma